arrow
A

Anna Polakiewicz-Gilowska

breast cancer center
H指数:6
被引数:613

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors

解析Ki67的作用:在CDK4/6抑制剂治疗晚期乳腺癌中的预后启示

2026-02-130
OAAI
Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort

接受sacituzumab govitecan治疗的转移性三阴性乳腺癌患者的联合阳性评分状态: 中欧队列中的相关临床特征和测试模式

2026-02-020
PRE
Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe
2026-01-240
OA
Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study

sacituzumab govitecan在预先治疗的三阴性乳腺癌和脑转移患者中的真实结果: 来自CEBCC-102研究的数据

2026-01-140
PRE
Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study
2026-01-120
OAAI
Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel

基线FDG PET/CT对接受一线曲妥珠单抗、帕妥珠单抗和多西他赛治疗的HER2阳性转移性乳腺癌的预后价值

2025-12-100
OAAI
Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study

Sacituzumab govitecan在转移性化生性三阴性乳腺癌患者中的疗效与安全性:一项来自CEBCC-102研究的跨国回顾性病例系列研究

2025-12-090
OAAI
Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety

Sacituzumab Govitecan在波兰转移性三阴性乳腺癌患者中的初始剂量降低:对疗效和安全性的影响

2025-10-040
OA
Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights

曲拉妥珠单抗(sacituzumab govitecan)治疗三阴性乳腺癌患者的预用药及粒细胞集落刺激因子(G-CSF)应用策略:多中心见解

2025-09-280
OA
Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis

基线血红蛋白和嗜中性粒细胞与淋巴细胞比值作为接受sacituzumab govitecan治疗的转移性三阴性乳腺癌患者(二线及以上治疗)的预后生物标志物:一项真实世界分析

2025-09-270
OA
Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study

Sacituzumab Govitecan用于三阴性乳腺癌患者的二线和后续姑息治疗: 一项波兰真实世界多中心队列研究

2024-09-270
OAAI
Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis

定制细胞周期蛋白依赖性激酶4/6抑制剂进展后的晚期乳腺癌治疗-真实世界数据分析

2024-06-070
OAAI
Fdg PET/CT early response prediction for triple negative breast cancer neoadjuvant chemotherapy with addition of carboplatin

Fdg PET/CT联合卡铂对三阴性乳腺癌新辅助化疗的早期疗效预测

2022-02-150
PRE